Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 678Thoracic 597Gynecologic 575Gastrointestinal 389Head & Neck 159Genitourinary 125Other solid neoplasm 97Tumor-Agnostic 85Dermatologic 49Sarcoma 44CNS 27Lymphoid 23Other hematologic neoplasm 19Endocrine 18Plasma cell 5Other neoplasm 5Other 2NET 2Classical hematology 2Myeloid 1

Conditions

Triple Negative Breast Neoplasms 1Fanconi Anemia, Complementation Group D1 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms 1Anemia 1

Interventions

Cyclophosphamide 93fludarabine phosphate 86Busulfan 63Cyclosporine 57Peripheral Blood Stem Cell Transplantation 54Mycophenolic Acid 54Whole-Body Irradiation 53Epoetin Alfa 53Antilymphocyte Serum 43fludarabine 42Filgrastim 41Cytarabine 41Tacrolimus 39Melphalan 38Darbepoetin alfa 38Methotrexate 34Radiotherapy 32Cord Blood Stem Cell Transplantation 28Granulocyte Colony-Stimulating Factor 23Methylprednisolone 21Etoposide 21apixaban 18eltrombopag 16Thiotepa 16Dalteparin 16ferric carboxymaltose 14Daunorubicin 14Azacitidine 14Alemtuzumab 14thymoglobulin 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Paclitaxel × Classical hematology × Clear all
NCT05485766 2025-03-20

Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer

Okayama University

Phase 2 Recruiting
23 enrolled
BreastClassical hematology

Fanconi Anemia, Complementation Group D1, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT00189371 2005-09-19

Reinduction Chemotherapy Containing Carboplatin and Paclitaxel With or Without Epoetin Alpha in Recurrent Platinum Sensitive Ovarian Cancer, Cancer of the Fallopian Tube or Peritoneum

AGO Study Group

Phase 3 Terminated
300 enrolled
Classical hematologyGynecologic

Carcinoma, Ovarian Epithelial, Anemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡